Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company leveraging artificial intelligence, announced it will host a webcast on Aug. 14, 2026, at 9 a.m. ET to discuss its second-quarter 2026 operating and financial results. The webcast will feature President and CEO Panna Sharma and other management team members, who will review the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company’s RADR(R) and Open-Medicine AI platforms. A replay will be available on the investor relations section of Lantern Pharma’s website following the event.
This announcement is significant for investors and the oncology community as it signals Lantern Pharma's continued progress in integrating AI into drug development. The company's proprietary RADR(R) platform is designed to transform cancer therapy development by using AI and machine learning to identify patient populations most likely to respond to its drug candidates. The upcoming webcast will likely shed light on the clinical pipeline, including LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound), and LP-300 (a cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
A key development to watch is the commercial availability of withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, which is now offered as a subscription-based research tool for the global biomedical and drug development community. This represents a new revenue stream for the company, potentially diversifying its income beyond traditional biotech funding. The webcast may provide more details on the adoption and early traction of this platform, which could be a pivotal factor in Lantern's financial outlook.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company's focus on AI-driven precision oncology positions it at the intersection of two high-growth sectors: artificial intelligence and biotechnology. As the pharmaceutical industry increasingly turns to AI to reduce costs and accelerate drug discovery, Lantern's progress could serve as a bellwether for the field.
Investors and analysts will be keen to hear updates on clinical trial enrollment, data readouts, and any potential partnerships or licensing deals. The webcast offers a platform for management to address these topics and provide guidance on near-term catalysts. With the commercial launch of withZeta.ai, there is also interest in how this platform will contribute to the company's financial performance and whether it can gain traction among research institutions and biotech firms.
The announcement of the webcast itself underscores Lantern's commitment to transparency and communication with its shareholders. By providing regular updates on its operations and strategic direction, the company aims to build investor confidence. The second-quarter results will offer a snapshot of the company's financial health, including cash runway and burn rate, which are critical for a clinical-stage biotech.
For more information, the full press release is available at https://ibn.fm/l80kv. Additional details about the company and its news can be found in its newsroom at https://ibn.fm/LTRN.
